Compare Novo Nordisk A/S (NVO) vs Sun Life Financial Inc. Common Stock (SLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sun Life Financial Inc. Common Stock — how do they compare? Novo Nordisk A/S trades at $39.58 (market cap $169.24B), while Sun Life Financial Inc. Common Stock trades at $78.26 (market cap $43.44B). The key difference: Novo Nordisk A/S is far larger — about 3.9× Sun Life Financial Inc. Common Stock's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Sun Life Financial Inc. Common Stock for 0 Days on average.
| NVO | SLF | |
|---|---|---|
Market Cap | $169.24B | $43.44B |
Volume | 9,314,273 | 333,821 |
Sector | Health | Financials |
52-Week High | $63.98 | $84.07 |
52-Week Low | $35.29 | $57.60 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $187.94B | $45.17B |
Dividend Yield | 4.71% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.06, down 1.35% with bearish technical signals despite strong fundamentals. The stock shows robust profitability with 35.35% net margins and consistent earnings beats. Recent FDA delays for hemophilia drug denecimig and competitive pressure from Eli Lilly's obesity drug pipeline create near-term headwinds. Technical indicators show RSI at overbought levels with resistance at $39.
Despite current technical weakness, NVO maintains strong fundamentals with 59% ROE and attractive valuation at 9.32 P/E. Analyst consensus remains bullish with $42.33 price target (11% upside). Key risks include regulatory delays and intensifying GLP-1 competition. The company's $4B licensing deals and oral Wegovy development provide long-term growth catalysts.
Sun Life Financial (SLF) trades at $77.87, up 0.69% on the day, reflecting steady momentum. The stock shows consistent earnings beats in recent quarters, with Q3 2026 results pending. Financial health is solid, with a P/E of 18.82 and robust cash flow projections for 2026. Recent strategic moves include expanding disability benefits and forming a reinsurance partnership, signaling growth initiatives.
The outlook for SLF is cautiously optimistic, supported by earnings strength and strategic expansions. Key risks include competitive pressures and macroeconomic volatility. Analyst sentiment is mixed, with a majority hold rating, suggesting potential stability but limited near-term upside. Investors should weigh solid fundamentals against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sun Life Financial Inc. Common Stock
Sun Life Financial Inc. is a Canada-based financial services company providing insurance, wealth and asset management, and health solutions for individuals and institutions. Its products span life, health, and disability insurance along with mutual funds and pension asset management, through operations in Canada, US, the United Kingdom, Ireland, and across Asia.
Read more on SLF →
